Chinese innovative pharmaceutical company, HENGRUI PHARMA (01276.HK), announced its IPO details, proposing to offer 225 million shares globally, with Hong Kong public offering accounting for 12.3486 million shares and international offering for 212 million shares.

The offer price per share ranges from $41.45 to $44.05. Based on 200 shares per board lot, the entry fee for one board lot is $8,898.85. The IPO starts today (15th) and will close at noon next Tuesday (20th), with the shares expected to be listed next Friday (23rd). The joint sponsors are Morgan Stanley, Citi Research and Huatai International.

The company introduced seven cornerstone investors, including GIC, Invesco Advisers, UBS AM Singapore, Cordial Solar, Hillhouse, Millennium and Oaktree, which subscribed a total of US$533 million (approx. $4.131 billion) worth of shares.
(HK stocks quote is delayed for at least 15 mins.)